Sanofi (SNY) is preparing to launch an improved bid for Ocular Therapeutix (OCUL), Investor’s Business Daily’s Allison Gatlin reports. Ocular CEO Pravin Dugel previously sold Iveric Bio to Astellas Pharma (ALPMY) for $5.9B in 2023, the report notes. Ocular Therapeutix is working on treatments for a number of eye diseases, including diabetic retinopathy, wet AMD and retinal vein occlusion. Shares of Ocular Therapeutix are up 2.6% to $11.36 in morning trading.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix rises 11.7%
- Ocular Therapeutix Enters Quiet Period Ahead of SOL-1 Milestone
- Strong Buy Rating for Ocular Therapeutix Backed by Enhanced Regulatory Pathway and Promising Axpaxli Trial Data
- Ocular Therapeutix price target raised to $21 from $18 at BofA
- Mizuho remains bullish on EyePoint as competitor makes move for ‘Pole Position’